Founded in Canada in 2015, Virogin aims to unleash synergy between oncolytic virotherapy and mRNA vaccines in the battle against cancer. Our vision is to be a global, best-in-class immuno-oncology company that creates impactful drugs for patients with the highest medical needs.
• Savvy pre-clinical and clinical teams with >25 years of successful experience leading to numerous regulatory milestones in the US and China
• Immunomodulatory payloads armed oncolytic tumor vaccines (OV) to overcome the immunosuppressive tumor microenvironment
• Demonstrated clinical safety and efficacy of OV monotherapy in various therapeutic areas
• Durable anti-tumor efficacy elicited by combining OV with mRNA vaccines overcoming hurdles presented in tumor vaccines
• Established capability of process development and manufacturing with extensive experience and know-hows in virus and mRNA-based therapeutics production
